Matteo Fila, MD

MD, Thoracic Oncologist, Humanitas Bergamo, Italy// Lung Cancer Research Program at @mayoclinic AZ Opinions are my own

[Hidehito HORINOUCHI @HHorinouchi]

🔥Improving neoadjuvant and perioperative therapy in NSCLC
🆙 @NatRevClinOncol
🎯ctDNA, radiomics & baseline biomarkers complement pCR to refine patient selection & adapt perioperative strategy
🎙 @YGaritaonaindia @HwakeleeMD @MartinReck2 @FordePatrick Dr. Tina Cascone @DoctorJSpicer @MARIANOPROVENCI
#LCSM @OncoAlert @Larvol
https://t.co/ts54YBaBZm

[IASLC @IASLC]

The countdown to #WCLC26 is on.

Join the global thoracic oncology community in Seoul to explore the latest research, connect with colleagues from around the world, and help shape the future of lung cancer care.

Register today: https://t.co/3STop8biMh

#IASLC #LungCancer

[JAMA Oncology @JAMAOnc]

After discontinuing pembrolizumab among patients with advanced #NonSmallCellLungCancer survival outcomes were high and subsequent immunotherapy use was rare. https://t.co/tNt85UxmF3

[Diego A. Díaz-García @diegoadiazg]

🫁 Immunotherapy Rechallenge in NSCLC.

The largest meta-analysis to date (10 RCTs, n=3,081) showed that PD-(L)1 rechallenge provided modest OS (HR 0.91) and PFS (HR 0.89) benefits, with no ORR improvement.

No benefit was observed in primary resistance, while patients with acquired resistance appeared more likely to benefit (OS HR 0.86).
Resistance phenotype matters.

📖 Cancer Treatment Reviews.
DOI 👉🏻 https://t.co/dX9gvaj5yP

#CánCare #NSCLC #lcsm #ThoracicOncology #Immunotherapy #ICI

[Alfredo Addeo MD @Alfdoc2]

The randomized phase III trial evaluating time-of-day in NSCLC has been retracted due to major concerns regarding trial registration, protocol inconsistencies, and data integrity.https://t.co/CxaOoXlbGg
This should not discourage researchers working on chronotherapy. The question remains important,but it deserves answers generated through rigorous, transparent, and reproducible science. @PTarantinoMD @Timothee_MD

[OncoDaily Lung @OncodailyLung]

🫁 Does maintenance pemetrexed still add value after chemoimmunotherapy in advanced nonsquamous NSCLC?

A new propensity score-weighted analysis of US Veterans Affairs data compared maintenance pemetrexed plus pembrolizumab with pembrolizumab alone after induction treatment with platinum chemotherapy, pemetrexed, and pembrolizumab.

The study included 622 patients:

➡️ 473 received pemetrexed + pembrolizumab
➡️ 149 received pembrolizumab alone

The central finding:

Continuing pemetrexed was not associated with improved overall survival.

📌 Adjusted HR for death: 1.06
📌 95% CI: 0.83–1.36
📌 P = .62

At the same time, maintenance pemetrexed was associated with greater toxicity:

⚠️ Grade ≥3 acute kidney injury: aHR 3.35
⚠️ Neutropenia: aHR 2.86
⚠️ Anemia: aHR 1.65

The analysis also estimated that US government payer spending on maintenance pemetrexed reached $1.588 billion from 2017 to 2022.

This retrospective study cannot determine whether every patient should stop pemetrexed. Residual confounding remains possible despite propensity weighting.

Still, the findings raise an important question for the immunotherapy era:

Should legacy chemotherapy maintenance strategies be prospectively reassessed when their independent survival contribution is uncertain?

Reference: Strohbehn et al. JCO Oncology Practice.

@BrianBazzellRx @xelamb

#OncoDailyLung #NSCLC

[Laura Alder, MD @LauraAlderMD]

First @IASLC Grand Rounds! @BalazsHalmosMD presenting the outstanding work of the Career Development Committee. Improving mentorship and opportunities across the globe! 🫁 🌍 #LCSM @karenkellymd @bensolomon1

[Balazs Halmos @BalazsHalmosMD]

Puzzling update to Jazz up our World Cup weekend with sobering results of the confirmatory LAGOON trial not showing superiority of neither lurbi alone (in fact trending worse OS) nor lurbi/irinotecan vs SOC chemo (topo or irinotecan).

What does this do to current 2nd line lurbi approval and enthusiasm in maintenance setting w starlatamab looming large and new ADCs trying to take a big bite of small cell in the meantime?

Sounds like this is more of a murky LAGOON… not the blue one might have hoped for…

https://t.co/MOJneZGNkW

[Stephen V Liu, MD @StephenVLiu]

Integrated molecular and clinical analysis of thymic epithelial tumors reported @JCOPO_ASCO led by Dr. @chulkimMD - explains key differences between thymic carcinoma and thymoma and highlights targeting MTAP deletions as a potential viable strategy

https://t.co/gsB4bKW5Bo

[Dr David Berger BSc MBBS MRCP(UK) FRACGP-RG DTM+H @YouAreLobbyLud]

This is so very sad. It's been a rollercoaster three years. What a brave, good man.

https://t.co/YTyoYC9RMy

[Toni Choueiri, MD @DrChoueiri]

Detecting lung cancer 5 years before it happens, in @CellCellPress courtesy of the @CharlesSwanton group.

Astonishing translational work !

https://t.co/EvUmIGVLgs

[Matteo Fila, MD @MatteoFilaMD]

@DiFedericoMD @IASLC @DrMarkAwad @BRicciutiMD @MSKCancerCenter @HosseinBorghaei @marinagarassino @oncodaily @pecci_federica1 @OncodailyLung @OncoDailyIO Congrats! Massive one

[Masahiro TORASAWA, MD. PhD. @M_Torasawa]

Seven thoracic oncology studies from #ASCO26 were published simultaneously in leading journals! 🫁✨

Great to see so many major advances in thoracic oncology presented and published at the same time.

#LCSM @OncoAlert

[Stephen V Liu, MD @StephenVLiu]

Dr. Tina Cascone outlines rationale & science behind neoadjuvant and perioperative immunotherapy for early stage NSCLC at #ASCO26. How do we isolate the value of the adjuvant component after pCR or non-pCR? How do we best escalate non-pCR? ADC? Vaccine? Insightful discussion.

[Alfredo Addeo MD @Alfdoc2]

È una bella notizia e va giustamente festeggiata. Mi permetto solo di chiarire che il farmaco apre certo la porta ad un trattamento più efficace e che prolunga la vita dei pazienti. La malattia purtroppo resta terribile e comunque la sopravvivenza mediana con questo farmaco resta 13 mesi , quindi purtroppo molto bassa. Non voglio spegnere l’entusiasmo ma solo cercare di non creare confusione nei nostri pazienti

[Oncology Brothers @OncBrothers]

Day 3 #ASCO26 5 plenary highlights:

1. #PROTEUS: PeriOp/PostOp Apa in Prostate Ca

2. #SARC041: Adj Abema in dediff liposarcoma

3. #LIBRETTO432 : Adj Selpercatinib in NSCLC

4. #HARMONi6: 1L Ivonescimab in Sq mNSCLC

5. #RASolute302: 2L Daraxonrasib in Panc Ca

@ASCO

1/6

[Stephen V Liu, MD @StephenVLiu]

Results from phase III WU-KONG28 @NEJM: first line sunvozertinib vs carbo/pem for EGFR exon 20 insertion NSCLC (n=324). Sunvozertinib clear winner here: RR 59% vs 31%, DOR 11.2 vs 7.1m PFS 10.3m vs 7.5m, HR 0.65, 12m PFS 46% vs 27%. Note toxicity: diarrhea 87% (G3+ 14%). #ASCO26

[Hidehito HORINOUCHI @HHorinouchi]

🔥ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1
🆙 @JCO_ASCO
☑Latest update incorporating new evidence for ICI-based regimens in stage IV NSCLC
🎙Dr. Lyudmila Bazhenova @HHorinouchi
#LCSM @OncoAlert @Larvol
https://t.co/k4lOuFfjrl

[Matteo Fila, MD @MatteoFilaMD]

@BrunaPellini @raffcolo @lungoncdoc @Latinamd @dwightowenmd @JKaufmanLungNED @StephenVLiu Great work Bruna, congrats

[Lung Cancer Europe @LungCancerEu]

A 🆕 30-page review in Cell maps the state of ADCs (antibody-drug conjugates) - the “magic bullet” cancer therapy first imagined in 1907.

19 approved. 260 in development. SCLC: zero.

Non small cell #lungcancer has genuine options now. But the review is direct about the gaps: patient selection, toxicity management, and tumours that are simply hard to reach.

https://t.co/tIH7uQbFrC #LCSM